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In the United States, influenza causes approximately 36,000 deaths and over 200,000 
hospitalizations each year with elderly most often affected. Clostridium difficile infection 
(CDI) is another major health care challenge and pressing public health issue associated 
with 14,000 deaths and over 335,000 hospitalizations annually. The use of antibiotics has 
been implicated in the development of CDI. This study’s purpose was to test the 
relationship of seasonal influenza incidence and antiviral/antibiotic use in CDI 
development among hospitalized patients. Grounded in the epidemiologic wheel model 
of man-environment interactions, this retrospective observational study described and 
analyzed data from a proprietary, laboratory, and pharmacy-based system from a cohort 
of hospitals. The association between 147 patients with a diagnosis and/or positive test 
for influenza, the independent variables of delivery of antivirals/antibiotics (n = 130) 
during the patient’s hospitalization, and the dependent variable of positive test or 
diagnosis of CDI (n = 17) was tested using multiple logistic regressions. The study results 
did not prove to be significant for the 3 research questions, suggesting no impact of 
antiviral use (R
2
 = .05, p = .336), antibiotic use (R
2
 = .05, p = .290), or antiviral and/or 
antibiotic use (R
2
 = .04, p = .382) on development of CDI within 60 days of discharge. 
However, findings indicated that recommended antiviral medication was inconsistently 
administered to influenza positive patients and that inappropriate prescribing patterns for 
antimicrobial agents coincided with seasonal influenza. Implications for positive social 
change include confirming the importance of antibiotic stewardship as an essential aspect 
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Chapter 1: Introduction to the Study  
Background 
The word influenza is derived from the Latin “influentia,” meaning influence of 
the stars. This star influence was thought to be the cause of influenza epidemics by 
ancient populations (Nelson & Williams, 2007). The Clostridium difficile organism is 
difficult to isolate in culture, requiring anaerobic conditions and special culture media, 
leading to the name Clostridium difficile (Isada, Kasten, Goldman, & Aberg, 2003). 
Individually, the prevalence of influenza and Clostridium difficile represent public health 
issues. Therefore, a study opportunity exists to gather insight and determine the details of 
the type of relationship between these two organisms. 
In Chapter 1, I provide background information and a platform of clinical 
descriptive facts about influenza and Clostridium difficile. For the purpose of this study, I 
provide evidence of the influenza virus complex structure and epidemiology, the 
financial, morbidity, and mortality burden this organism has on society, and the impact 
the influenza vaccine plays in prevention. Additionally, Clostridium difficile 
microbiology, epidemiology, statistics, burden, and role of antimicrobial stewardship will 
be discussed. 
Influenza Microbiology and Clinical Description  
Influenza is a highly contagious illness caused by the orthomyxoviruses. The 
influenza virus is an enveloped, eight-segmented, single-stranded, helical shaped 
ribonucleic acid (RNA) virus from the orthomyxovirus family (Orthomyxovirus, 2012). 




differences of internal proteins (Isada et al., 2003). Influenza type A is the most common 
form of influenza and is found to attack in epidemic proportions in humans and other 
animals. Type B is not as common as A and generally causes outbreaks every 2 to 4 
years. Type C is the least common, causing milder forms of sporadic infection. All three 
groups of influenza viruses frequently mutate due to the small amount of RNA genetic 
material within a virus (Influenza, 2003).  
Orthomyxoviruses cause illness when they gain entry into host cells and replicate 
within them (Influenza, 2003). The new viruses explode from the host cell and infect 
other cells. Orthomyxoviruses are sphere-shaped viruses that contain RNA. The virus’s 
RNA is used like a blue-print plan for replication within host cells. The outer envelope of 
an orthomyxovirus is studded with protein spikes that aid the virus to invade host cells 
(Influenza, 2003). There are two different types of spikes on the virus's outer envelope; 
one type is composed of hemagglutinin (H) protein (Influenza, 2003). The H protein 
fuses with the host cell membrane and allows the virus particle to enter the cell. The 
second type of spike is made of the neuraminidase (N) protein (Influenza, 2003). The N 
protein helps the newly formed virus particles to bud out from the host cell membrane 
(Influenza, 2003).  
In the envelope transmembrane protein spike H, there are three types, and N has 
two types. This ability to mutate allows the virus to cause frequent outbreaks. The 
mutations occur from the gradual and continuous antigenic changes in the H and N 
proteins. Subtle changes, typically in the H protein, are termed “antigenic drift,” 




Sudden and significant changes in the H and N proteins are termed “antigenic shift” and 
are responsible for influenza pandemics (Nelson & Williams, 2007). Strains of influenza 
are labeled according to a standard naming convention of the type of internal protein: A, 
B, or C; the location where the strain was first identified; strain number from isolating 
laboratory; year of isolation; and the virus subtype or H/N type (Nelson & Williams, 
2007). Some examples include A/California/7/2009/H1N1 and A/Fujian/411/2002/H3N2 
(Nelson & Williams, 2007).  
Influenza Epidemiology 
Influenza is a highly infectious viral illness and the cause of worldwide 
respiratory disease. It is spread person to person by inhalation of aerosolized droplets that 
contain the virus and exposure to contaminated fomites (Heymann, 2008). Recurrent 
episodes of influenza happen every 1 to 3 years due to “antigenic drift” and have been 
observed for over 400 years (Isada et al., 2003). Worldwide pandemics caused by 
antigenic shift occur every 10 to 20 years and result in high mortality rates (Isada et al., 
2003). The epidemic or pandemic population response varies in the size and impact due 
to the degree of antigenic variation, virulence of the new virus, and the level of protective 
immunity of the affected population (Nelson & Williams, 2007). The Centers for Disease 
Control and Prevention (CDC) reports, in North America seasonal influenza epidemics 
usually occur between November and March each year with peak months typically being 
January and February (CDC, 2009). These epidemics are characterized by high attack 
rates of 10 to 20% of the population (Nelson & Williams, 2007). The results are 




increased pneumonia, influenza related hospital admissions, and death from influenza and 
influenza complications. Common complications from the flu can include coinfections 
with other viral or bacterial organisms, primary viral pneumonia, exacerbation of 
underlying medical conditions such as pulmonary and cardiac diseases, secondary 
bacterial pneumonia, sinusitis, and otitis media (CDC, 2011). Viral spread during North 
American winter months is a result of the influenza virus’s increased survival in lower 
temperatures and humid environments. Additionally, indoor crowding caused by weather 
may lead to viral spread (Nelson & Williams, 2007).  
Influenza Statistics and Burden 
Each year, influenza causes approximately 36,000 deaths in the United States and 
over 200,000 hospitalizations (CDC, 2007b). Rates of infection are higher in infants and 
children than adults, which is often attributed to children being immunologically naïve to 
the virus (CDC, 2009). The rates of hospitalization are highest among infants and elderly 
(CDC, 2009). The economic impact of the flu is greater than $80 billion annually in the 
form of hospital costs, outpatient visits, loss of life, and missed days of work (Klepser & 
Hagerman, 2011). Data released from the CDC indicated that influenza vaccination 
coverage remains low in adults and children (CDC, 2009). During the 2005 to 2006 flu 
season, one in five children ages 6 to 23 months were fully vaccinated, and many other 
children who needed to receive the two dose regimen only received one dose (CDC, 
2007). Throughout the United States, no state had more than 40% of children fully 
vaccinated and significantly fell below the 60% target for high risk people ages 18 to 64 




coverage was 30.5% for 18 to 49 year olds in high risk categories, 18.3% in nonhigh risk 
of this same age group, 36.6% in adults 50 to 64 years old, and 69.3% in adults who were 
65 and older (CDC, 2007c). However, Healthy People 2020 objectives outline to increase 
the proportion of children and adults who are vaccinated annually against seasonal 
influenza, thereby improving vaccination for all ages (U.S. Department of Health and 
Family Services, 2012). 
Influenza Vaccine Use 
The fall and winter months in the United States are when the influenza virus 
causes disease, illness, and death. Each flu season, there are hundreds of thousands of 
hospitalizations and deaths due to the virus. Many hospitalizations and death could be 
avoided because the use of the influenza vaccination can prevent the infection and its 
health complications (CDC, 2010). The vaccine is targeted and recommended for use in 
individuals at risk of influenza complications and to reduce the transmission of flu to 
others. In particular, the attack rate of the seasonal illness from the flu is of concern 
among individuals 65 years and older, in which the death rate from influenza is greatest 
(CDC, 2009). The CDC’s Advisory Committee on Immunization Practice (ACIP) 
provides the annual recommendations for flu prevention strategy efforts. The ACIP 
examines vaccine effectiveness, coverage, supply, safety, and efficacy. The influenza 
vaccine must be given annually because the circulating strains change slightly each year, 
and the vaccine must be formulated to match what the predicted strains will be. Despite 
efforts to improve the number of people who receive a yearly influenza vaccine, vaccine 




virus complicates efforts to aggressively vaccinate the public, as was seen in the recent 
years from the H1N1 circulating strain (Klepser & Hagerman, 2011). 
Clostridium difficile Microbiology and Clinical Description 
Clostridium difficile, another variable that was considered in this study, is a gram-
positive, spore forming, anaerobic rod (Isada et al., 2003). It is the most frequent cause of 
colitis associated with antibiotic use (Nelson & Williams, 2007). This bacterium can live 
in the gut of infant and adult carriers causing no harm, but it can lead to severe diarrheal 
disease in susceptible people. Clostridium difficile infection (CDI) commonly causes 
diarrhea but has been linked to the more severe disease of pseudomembraneous colitis 
and toxic megacolon (Drekonja et al., 2011). Clostridium difficile can produce two 
toxins: A and B; these “exotoxins” cause damage to the colon and result in diarrheal 
illness (Isada et al., 2003). Certain environmental conditions are required for expression 
of the toxigenic process within the intestinal lumen. The more common toxin A is 
described by Isada et al. as an “enterotoxin” and B as a “cytopathic” toxin. Most strains 
causing diarrheal illness produce both A and B toxin; however, there are cases where 
only one of the two toxins is expressed. There are a number of nontoxigenic Clostridium 
difficile strains that lack the gene for toxin A and B and do not cause diarrheal illness. 
Clostridium difficile toxin production is of clinical importance and relevance to detect by 
laboratory methods because the toxins cause inflammation and damage of the intestinal 
wall in addition to secretion of fluid into the intestinal lumen that can lead to necrosis of 
the colonic mucosa (Farrow et al., 2013; Isada et al., 2003). Garey (2011) described the 




increased toxin production and a higher rate of sporulation, resulting in increased 
morbidity and mortality in the United States. Therefore, Clostridium difficile can produce 
no toxins, low levels of toxins, or be highly toxigenic. 
The Clostridium difficile organism can be found in two forms: a vegetative form 
and spore form. The vegetative form is sensitive to oxygen and is easily killed in the 
environment (Isada et al., 2003). The spore form is hardy and heat stable, allowing it to 
survive in even the most inhospitable conditions of gastric acids and endure many 
commercial disinfectants (Isada et al., 2003).  
Clostridium difficile Epidemiology 
Risk factors for acquisition of CDI are exposure to antibiotics, hospitalization, 
and advanced age with a decreased immune response (APIC, 2008). CDI is most 
commonly associated with exposure to antibiotics and the acquisition of Clostridium 
difficile from fecal-oral transmission. Some people will develop CDI and its associated 
clinical diseases while others will only be asymptomatic and colonized. According to 
APIC, the “pathogenesis” of Clostridium difficile acquisition involves oral ingestion of 
spores that resist the acidity of the stomach and germinate into vegetative bacteria in the 
small intestines. Exposure to antibiotics alters the normal intestinal flora and provides the 
environmental conditions for Clostridium difficile to multiply, thrive, and potentially 
produce toxins that cause mucosal damage. Garey (2011) described nearly all antibiotics 
have been implicated as the causative agent in the development of CDI. In particular, 
broad spectrum antibiotics, antibiotics that eliminate anaerobic flora, and certain 




highly implicated (APIC, 2008; Gerding, 2004). Antibiotics are the cause of the 
suppression of normal intestinal flora and this permits the overgrowth of Clostridium 
difficile, which can result in high levels of toxins to be produced (Isada, 2003). In 
contrast, Isada described when the selective pressure of antibiotics is not present, the 
acute infection with Clostridium difficile is self-limited and the person is asymptomatic 
afterwards. 
“Colonization” with Clostridium difficile can be found in people of all ages and 
not be associated with clinical disease. The organism can be cultured from healthy adult 
stool 3% to 5%, and among hospitalized adults, 10% to 30% are colonized with this 
organism (Isada, 2003). Colonization can occur with toxin-producing strains and 
interpretation of stool tests for Clostridium difficile should be correlated with diarrhea 
and symptoms (APIC, 2008).  
Clostridium difficile Statistics and Burden 
The CDC (2012) reported between the years 2000 to 2009 an increase in the 
number of patients with CDI in any discharge diagnosis doubling from 139,000 to 
336,600 and the number with a primary diagnosis of CDI tripling from 33,000 to 
111,000. Additionally, the CDC described Clostridium difficile was associated with 
14,000 deaths, with more than 90% in > 65 years of age, and over 335,000 annual 
hospitalizations, Garey (2011) reported the cost of CDI ranges from $433 to $797 million 
annually. The CDC reported excess healthcare costs of hospital-onset CDI as $5,042 to 
$7,179 per case with a national annual estimate exceeding $1 billion dollars (CDC, 




attributable cost of hospital-onset CDI at $6,117 per case. Additionally, Tabak et al. 
discovered patients with hospital-onset CDI lengths of stay were 2.3 days longer and 
experienced a statistically significant higher mortality rate of 4.5% for in-hospital 
attributable mortality effect compared to endemic setting attributable mortality of 1 to 
2%. The CDC has reported Clostridium difficile is no longer just a hospital issue, with 
almost 94% of CDI occurring in people who recently received medical care in or out of 
the hospital setting. Furthermore, 75% of infections have an onset in nursing home 
settings or in people who were recently cared for in an outpatient medical setting (CDC, 
2012b). 
One aspect of quality health care that can prevent the occurrence of CDI is 
antimicrobial stewardship (CDC, 2012b). The CDC reports the risk of CDI development 
increases by seven to 10 fold while a patient is taking antibiotics, and this risk persists for 
1 month after discontinuation of antibiotics. Additionally, this risk is three fold for the 
next 2 months post antibiotics use (CDC, 2012b). 
Influenza continues to be unpredictable as new and emerging strains occur, 
making the reality that influenza related illness and hospitalizations will continue despite 
best efforts to immunize the population. The rates of CDI continue to increase nationally. 
Of concern is the impact this disease has on the aging population where the risk factors 
for acquisition are more pronounced: exposure to antibiotics, hospitalization, and 
advanced age with a decreased immune response. In summary, both influenza and 




terms of hospitalization, morbidity, mortality, and economics related to management of 
these diseases. 
Problem Statement 
Annually influenza causes thousands of deaths in the United States and hundreds 
of thousands hospitalizations (CDC, 2010). CDI has emerged as the most common cause 
of antibiotic-associated diarrhea and a highly problematic healthcare-associated infection 
(Garey, 2011). Nearly all antibiotics have been implicated in CDI, with certain 
antimicrobial classes causing higher risk for disease (APIC, 2008). Use of antibiotic 
agents can vary by season (Gelband, 2009; Linder, Bates, & Platt, 2005). Seasonal 
antibiotic use may indicate inappropriate prescribing patterns (Polgreen, Yang, Bohnett, 
& Cavanaugh, 2010). CDI does follow a seasonal pattern that peaks in mid-March in the 
United States (Jagai et al., 2007). Incidence of CDI may be related to the incidence of 
seasonal influenza; however, most of the literature  reviewed revealed access limitations 
to clinical, microbiologic, and dispensed antibiotic data in the same databases, and no 
readily available national data that aggregate the monthly receipt of antibiotic agents in 
hospitalized populations (Polgreen et al., 2010). This limitation has made it difficult to 
draw conclusions about the role antibiotics may have in the development of CDI during 
flu seasons. Therefore, this study addressed a problem of using a database that includes 
microbiologic, antibiotic, and antiviral agent use in hospitalized patients. Use of a 
database rich in these elements in this study helped improve understanding of the 
development of CDI during influenza seasons. The potential for social change exists, 




activity, and further implying reasons to prevent influenza through immunization and 
focus appropriate antibiotic/antiviral use during the influenza season.  
Purpose of the Study 
The purpose of this quantitative study was to examine the temporal progression of 
CDI incidence and the possible influence that seasonal variation of influenza and 
antibiotic and antiviral use has on the incidence of CDI. An enhanced understanding was 
determined about the relationship of CDI and seasonal influenza and the role/influence of 
antibiotic use and selection. The study’s significance further contributed to the growing 
body of knowledge of the implications that antibiotic use has on CDI. In this study, I 
determined if the overuse and/or inappropriate use of antibiotics has an impact on the 
development of CDI during seasonal disease outbreaks of influenza.  
Research Questions and Hypotheses 
 This study was guided by the following research questions: 
 Research Question 1: Is there a relationship between use of prescription antivirals 
and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza? 
 H01: There is not a statistically significant association between use of prescription 
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
 Ha1: There is a statistically significant association between use of prescription 





Research Question 2: Is there a relationship between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza? 
 H02: There is not a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
 Ha2: There is a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
Research Question 3: Does the use of prescription antivirals and/or prescription 
antibiotics predict CDI within 60 days of discharge in patients who have been 
hospitalized for influenza? 
 H03: The use of prescription antivirals and/or prescription antibiotics does not 
predict CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
 Ha3: The use of prescription antivirals and/or prescription antibiotics does predict 
CDI within 60 days of discharge in patients who have been hospitalized for influenza. 
Theoretical Foundation 
The epidemiologic wheel is a model of disease causation that brings together the 
outer wheel segments of physical, social, and biological environment factors with two 
inner circles, with genetics nested in the host circle (Davis, 2000). The wheel of causation 




disease (Peterson, 1995). This model was used as the theoretical foundation for this study 
and is discussed further in Chapter 2. 
Nature of the Study 
A retrospective, observational design was used to describe and analyze the 
relationship between the incidence of CDI and the variables of antiviral/antibiotics 
among an influenza positive population. The data were abstracted using a convenience 
sample from a propietary database. This database receives hospital data feeds of 
admission, transfer, and discharge (ADT), laboratory microbiologic, and pharmacy data. 
The collected patient data were queried and abstracted for study variables; the 
independent variables’ delivery of antiviral/antibiotics as well as the dependent variable 
of positive test or diagnosis of CDI among patients with a diagnosis and/or positive test 
for influenza was analyzed using multiple logistic regression.  
Definition of Terms 
The following section provides definitions of terms and phrases that were used to 
describe concepts and variables important to this study. 
Antibiotic: “A drug that is used to kill harmful bacteria and cure infections” 
(Antibiotic, 2013). 
Antigenic drift: “The ‘evolutionary’ changes that take place in the molecular 
structure of DNA/RNA in microorganisms during their passage from host to another. It 
may be due to recombination, deletion, or insertion of genes, to point mutations, or to 




immunological responses of individuals and populations to exposure to the 
microorganisms concerned” (Porta, 2008, p. 7). 
Antigenic shift: “A mutation, or sudden change in the molecular structure of 
DNA/RNA, in microorganisms, especially viruses, that produce new strains of 
microorganisms. Hosts previously exposed to other strains have little or no acquired 
immunity. Antigenic shift is believed to be the explanation for the occurrence of strains 
of influenza associated with large-scale epidemics and pandemic spread” (Porta, 2008, p. 
7). 
Antimicrobial: “Any drug, medication, or agent that acts to destroy bacteria” 
(Rothenberg, 1999, p.23). 
Antimicrobial stewardship: “Coordinated interventions designed to improve and 
measure the appropriate use of antimicrobial agents by promoting the selection of the 
optimal antimicrobial drug regimen dosing, duration of therapy, and route of 
administration” (Society for Healthcare Epidemiology of America [SHEA], Infectious 
Diseases Society of America [IDSA], & Pediatric Infectious Diseases Society [PIDS], 
2012, p. 323). 
Antiviral: “Opposing a virus, weakening or abolishing its action” (“Antiviral,” 
1972, p. 86). 
Clostridium difficile: “A gram-positive, spore forming, anaerobic rod which 
causes millions of human infections each year, with an increasing incidence in recent 




Colonization: “Presence of organisms in or on the body site, but not causing 
clinical signs or symptoms of infection” (“Colonization,” 2002, p. 69). 
Cytopathic: “Pertaining to a diseased condition of a cell” (“Cytopathic,” 1972, p. 
319). 
Enterotoxin: “A toxin that is produced by microorganisms and causes 
gastrointestinal symptoms” (“Enterotoxin,” 2012). 
Exotoxin: “A protein produced by a bacterium and released into its environment 
causing damage to the host by destroying other cells or disrupting cellular metabolism” 
(APIC, 2008, p. 7). 
Influenza: “An acute viral disease of the respiratory tract characterized by fever, 
cough (usually dry), headache, myalgias, prostration, coryza and sore throat” (Heymann, 
2008, p. 315) 
Influenza antiviral agent: “Four licensed prescription antiviral agents available in 
the United States: amantadine, rimantadine, zanamivir, and oseltamivir” (CDC, 2011, p. 
6). 
Influenza diagnostic tests: “Diagnostic tests available for influenza include viral 
culture, serology, rapid diagnostic (antigen) testing, reverse transcription polymerase 
chain reaction (RT-PCR), and immunofluorescence assays” (CDC, 2011, p. 4). 
Pathogenesis: “The mechanisms by which a cause or etiological agent produces 




RT-PCR: “Reverse transcription polymerase chain reaction is a method to amplify 
small quantities of the nucleic acid of a microorganism so the microorganism can be 
detected by other molecular biology means” (Isada et al., 2003, p. 553). 
Seasonal variation: “Change in physiologic status or in disease occurrence that 
conforms to a regular seasonal pattern” (Porta, 2008, p. 225). 
Assumptions and Limitations 
Assumptions 
In this research, I assumed that the established risk factors for exposure to 
antibiotics and antivirals during the influenza season were not significantly different 
among the U.S. hospitals in this study. Jarvis et al. (2009) studied hospitalized patients 
and found 79% of patients received antibiotics prior to Clostridium difficile associated 
disease (CDAD). It is assumed for the purpose of this study that antibiotic/antiviral 
consumption will be similar across the hospitals used in the study data set.  
Another assumption was the diagnosis data received were based on clinical signs 
and symptoms and interpreted laboratory results from qualified healthcare professionals. 
Laboratory test results are assumed to be performed using Clinical and Laboratory 
Standards Institute standards, qualified laboratory professionals, and FDA approved tests. 
While the data were not directly collected by me, it was assumed the data were accurate. 
Limitations 
The data used in this study were collected for patient care and not for research. 




questionable. The study’s retrospective design may have had limits of interpretability 
because of the data accuracy.  
The study was limited to association of data and would not allow for a cause and 
effect inference because I did not directly collect the data. An observational, 
nonexperimental design limits the interpretation of the results (McPherson & Bunker, 
1991). I used a proprietary database from a set of hospitals that pay for the electronic 
surveillance system and pharmacy modules. This willingness to pay for these services 
made this group of hospitals unique in terms of their commitment to infection prevention, 
data collection, and antimicrobial monitoring. The collected research cohort increased 
sampling bias more than that seen in random sampling, while increased internal validity 
from the surveillance system’s organized, consistent methodology for isolate and 
antimicrobial results data. 
Additional limitations include that the patient data were not queried for 
documentation of underlying medical conditions that can be exacerbated by influenza 
infection, nor were they queried for secondary infections, coinfections, or complications 
from influenza. Moreover, documentation or knowledge of influenza vaccine receipt was 
not queried in the study population, and the patient’s immune response to the vaccine, if 
received, remained unknown.  
Scope and Delimitations 
Influenza causes thousands of deaths in the United States annually and hundreds 
of thousands hospitalizations (CDC, 2010), and CDI has emerged as the most common 




infection (Garey, 2011). The focus of this study, therefore, was to gather a convenience 
sample of information across U.S. hospitals. I used sampling from a group of hospitals 
that pay for an electronic surveillance system.  
For this study, long term care, rehabilitation, and children’s hospitals were 
excluded from sampling. Sampling was from acute care hospitals and adult patients. In 
long term hospital and rehabilitation settings, patients are often treated as residents and 
have healthcare issues and disease management that are not considered acute. Children’s 
hospitals were also excluded, as seasonal respiratory illnesses seen in the very young 
during the typical influenza season often manifest as respiratory syncytial virus (RSV) 
and other respiratory syndromes (Nelson & Williams, 2007). The CDC reports that 
during the influenza season, there are more outpatient visits in children 7 to 12 years old 
(CDC, 2010). Furthermore, among children age 5 to 7, there were more antibiotic 
prescriptions provided per 100 children than age 15 and younger compared to time 
periods when seasonal influenza is not circulating (CDC, 2010). Additionally, annual 
hospitalization rates for lab confirmed influenza decrease with increasing age (CDC, 
2010). Children are often less exposed to antibiotics in terms of years and the antibiotic 
choices selected by pediatricians and neonatologists. Therefore, data for lab confirmed 
influenza with inpatient antibiotic utilization among children would be more difficult to 
find.  
The cohort of hospitals used in the study may not accurately represent all United 






Researchers have shown the relationship of risk factors for CDI as exposure to 
antibiotics, hospitalization, and advanced age (AHRQ, 2012; APIC, 2008; Garey, 2011; 
Jarvis, Schlosser, Jarvis & Chinn, 2009). Little published literature exists supporting the 
theoretical aspects of how seasonal variations of influenza incidence and antibiotic use 
relate to CDI development in hospitalized patients. Influenza and CDI development 
studies have been limited by data sources, including administrative data versus clinical or 
microbiologic data (Polgreen, 2010). Furthermore, antibiotic use is an additional factor in 
this equation that has not been studied due to lack of readily available, nationwide data 
aggregating receipt of antibiotics in hospitalized patients or access to reliable antibiotic 
data in individual hospitalized patients (Polgreen, 2010). 
There are significant implications for social change. Knowledge from an 
epidemiologic study of seasonality of disease and antibiotics can have an influence at 
local and organizational levels. Healthcare providers can benefit from recognizing the 
affect that antibiotic delivery in hospitals and healthcare settings has through more 
informed choices for use and pharmacologic recommendations, in other words, through 
increased “antibiotic stewardship”. Jarvis et al. (2009) found the considerable morbidity 
and mortality associated with CDI calls for implementation of comprehensive evidence-
based Clostridium difficile measures. Antibiotic resistance and CDI are health care issues 
that affect the hospitalized patient and can have implications for affecting the general 
public once the patient is released from a healthcare setting, such as exposing the 





The epidemiology of CDI has changed over recent years. The attributable 
economic burden to healthcare providers and the added morbidity and mortality to 
patients makes this issue a public health concern. Influenza puts the population and 
public health into a conundrum every year as the virus shifts and drifts causing challenges 
for vaccine producers to provide a good match to the circulating strain. Vaccine receipt is 
an important part of reducing the incidence of influenza. The populations most at risk for 
complications of the flu are often hospitalized and die due to lack of prevention efforts 
such as annual vaccination. 
In Chapter 2, a review of the literature will be as analyzed to further describe the 
role of influenza, CDI, and antibiotic stewardship. This review is important to provide 
further understanding for the readers about the study variables and highlight what is 
known and where inconsistencies and gaps exist. From the analysis, a gap in the literature 
will be revealed and formulate the need for research. In Chapter 3, methodology, I will 
describe how the research was carried out, and I will discuss how the study answers the 
research questions and hypotheses. I will also describe the study variables, ethics, and 
data handling. Chapters 4 and 5 will outline the study results, discussion of the findings, 
and implications for social change. References and any appendices are provided in the 




Chapter 2: Literature Review 
Introduction 
The literature review was performed to gain a thorough understanding of the 
epidemiologic research related to Clostridium difficile, influenza, and the concept of 
antimicrobial stewardship. In order to comprehend the current models and beliefs of CDI 
development, the literature review includes a historic and current perspective of CDI 
epidemiology; searches for this literature were performed without date limitations in 
multiple databases. This literature search revealed hundreds of articles that were then 
narrowed to relevance for this study. 
The purpose of the literature review is to effectively discuss the problems 
associated with the development of CDI in the United States and reveal a gap in the 
literature for the variables of this study. The approach is to organize the literature into a 
basic historic and epidemiologic perspective of CDI through the history and 
microbiology of Clostridium difficile. The literature review also provides background 
information and data to support the problem of variability of physician ordering of 
antiviral/antibiotics use overall and during times of influenza incidence. Furthermore, the 
literature provides an understanding of the concept of antimicrobial stewardship and 
provides supporting literature of antimicrobial use related to the development of CDI. In 
the final portion of this chapter, I will discuss the literature related to the variables used in 
this study. Also drawn from literature are components of population and setting as a 





The literature search was conducted through multiple databases including 
EBSCOhost, MEDLINE, CINAHL Plus, and Cochran Collection Plus (through the 
Walden University library). In addition, searches were conducted through Google Scholar 
and the CDC website. Finally, the Michigan eLibrary and Ironwood Carnegie Library 
were used to search for literature. EBSCOhost MEDLINE full text search for scholarly 
peer reviewed journals, years 2000 to 2013 revealed the following: 147 results using the 
terms influenza and antibiotics, 113 results using the terms influenza and antivirals, 47 
results using the term antibiotic stewardship, and 949 results using the term Clostridium 
difficile. ProQuest search of peer reviewed articles, years 2009 to 2013, using terms 
influenza and antibiotics, revealed 54 results with one article used. Also searched were 
the CDC’s primary peer-reviewed publication, Morbidity and Mortality Weekly Report, 
and I used my own peer reviewed journal holdings and subscriptions of the American 
Journal of Infection Control and the American Journal of Public Health to search for 
articles of relevance. Use of bibliography mining for citation chains was a search strategy 
used from key articles that were of close relevance to my research questions. Any 
journals or books pertinent to the research were downloaded, purchased, or procured for 
use.  
A variety of terms were used to search for pertinent literature in the databases 
listed. The following common terms were searched: influenza and antibiotics, influenza 
and antivirals, Clostridium difficile, Clostridium difficile risk factors, Clostridium 




history of Clostridium difficile, seasonal influenza, and wheel model. Searches were also 
enhanced from article referrals from work colleagues who are pharmacists and have 
ready access to pharmacy journals and positions papers on the key subjects of 
antimicrobial stewardship, Clostridium difficile, and antibiotic and antiviral use. Faculty 
suggestions for articles were also incorporated into the literature review. Periodic 
searches have been conducted through the current month and year to ensure any newly 
published articles or positions statements of relevance are found for use. 
Theoretical Foundation 
Epidemiologic Wheel 
Mausner and Bahn (1974) described overall that models of disease have multiple 
causation. In the medical community, the focus is on the patient with forces and factors 
within the patient, the environment, and microorganisms contributing to disease. This has 
been depicted as the epidemiologic triangle with the corners of host, agent, and 
environment as labels. This model illustrates that a change in any of the components will 
ultimately alter the equilibrium of the triangle and increase or decrease the disease 
frequency (Mausner & Bahn, 1974). Mausner and Bahn first described the wheel model 
(see Figure 1). It is an elaboration of the man-environment concept with the host or man 
at the center, and the man has a genetic makeup nested at the core of this host hub that is 
surrounded by the environment, which is divided into three sections. These three 
sections--biological, social, and physical--can differ in size depending on the specific 
disease or problem. Diseases that are hereditary would have a large genetic core, while 




the host in the biologic environment section and social section may change in size when 
considering factors such as exposure to the virus, receipt of a preventative vaccine, or 
herd immunity. Mausner and Bahn stated that the wheel model “implies a need to 
identify multiple etiologic factors of disease without emphasizing the agent of disease” 
(p. 35). In addition, “the wheel model does encourage separate delineation of host and 





Figure 1. Wheel model of man-environment interactions. From Epidemiology: An 
introductory text (p. 36), by J. S. Mausner and A. K. Bahn, 1974, Philadelphia: Saunders. 
Copyright 1974 by W. B. Saunders Company. Reprinted with permission. 
 
The use of this theory relates to the study of understanding determinents of CDI, 
seasonal influenza, and the role/influence of antibiotic use and selection. The host or man 
at the center has the three sections of environment in play at many stages of the disease 
development of CDI. The development of influenza can be based on the lack of vaccine 
receipt, naïve host, or a vaccine mismatch due to a differing circulating/novel influenza 
strain (CDC, 2009). This section weighs heavy in the biological section, as does receipt 




biological factors of a dose-response relationship in the development of influenza with 
the occurrence of influenza based exposure to the associated influenza strain and the 
proportion of vaccine match for those who received it (CDC, 2009; Glezen, 2006). 
Admission to the hospital or the need to seek medical intervention for influenza is in the 
social and biological sections. This can have social constructs of individual, family, or 
cultural groups influencing the health seeking behavior and decisions to seek treatment. 
The physical environment includes exposure to Clostridium difficile spores in the 
physical hospital environment, and the social aspects include if the physician prescribes 
antibiotics that may alter the host gut to develop CDI, as well as the host request and 
acceptance of antibiotics. The physican’s desire to use antibiotics may be based on the 
need to provide comprehensive coverage for all upper and lower respiratory conditons 
without a clear etiology, not having or waiting for influenza testing results prior to the 
administration of antibiotics for bacterial infections versus antivirals for viral infections 
such as influenza, lack of critical thinking, physician’s need to do something for the 
patient, or maintaining patient satifaction as they request medications (Bonner, Monroe, 
Talley, Klasner, & Kimberlin, 2003; Linder et al., 2006). The social aspects of care for 
the host by the medical provider can greatly influence this portion of the wheel.  
Peterson (1995) used the wheel model to describe war and disease. The wheel 
model was used to detail the complexity of war conditions. This included concentrations 
of people and intermixing of populations. Additionally, resources that may be in short 
supply, such as basic hygiene and medical care, along with the diversion of food supplies 




rate of infectious disease and may lead to social disintegration. Peterson found this model 
to be more encompassing of multiple etiologic factors, which was necessary to fully 
explain the relationship between war and disease. Uzoigwe, Khaitsa, and Gibbs (2007) 
used the wheel model to describe the multiple etiologic factors that influence irritable 
bowel syndrome. They described the interaction of genetic and environmental factors that 
can influence the disease process, including infectious agents, diet, drugs, stress, and 
social status. The use of the wheel model by Peterson and Uzoigwe et al. provided 
examples of use for research questions that involve a complex set of factors. In this study, 
the model can also be used to describe the complexity of antivirals and antimicrobials 
with the influence of physician ordering and patient factors. 
Current Trends in Influenza 
Morbidity and mortality from influenza is linked to the underlying status of the 
host, and many factors such as age and comorbidities play a significant role in the 
acquisition and ultimate presentation of the disease. In the United States, influenza deaths 
have increased over the past 25 years with the highest attack rates among children under 
age 5 and individuals aged 65 and older (Klepser & Hagerman, 2011, p. 207). Influenza-
related complications and hospitalization are lowest among children (Klepser & 
Hagerman, 2011, p. 209). Aggressive vaccination for the seasonal flu can minimize the 
impact of health related influenza illness to populations. Glezen (2006) noted mortality 
and hospitalization due to influenza has increased despite increasing vaccine coverage to 
the most vulnerable populations. Furthermore, the most vulnerable populations are the 




the literature on novel strategies for influenza control that indirect effectiveness of the 
influenza vaccine could be obtained when children received the live attenuated vaccine 
and herd protection was conferred to adults. Herd immunity or herd protection of a group 
can occur when a large proportion of individuals from that group are immune or 
immunized to an infectious agent, thereby reducing exposure of those susceptible to that 
agent (Porta, 2008). Glezen also noted this same concept for herd protection occurred 
among Japanese school children where 50% to 85% of the student population was 
vaccinated using injectable vaccine. Traditional Japanese families live in 
multigenerational households, the conferred herd protection to the elderly in the 
household occurred as a result of the school children’s immunization. In contrast, Kelly, 
Kromelis, Jordan, Merryman, and Siegle (2012) used a novel strategy to deliver the 
influenza vaccine to primarily adult household contacts of infants aged less than 60 
months to increase vaccine uptake among household contacts and reduce household 
influenza transmission. The importance of this strategy illustrated it may be the only 
means to protect the very young as no influenza vaccine is available for infants aged less 
than 6 months. The CDC (2009) statistics indicated that serious illness and death are 
highest among children less than 2 years old and adults aged 65 years and older; adults 
aged 85 years and older are at the highest risk for death, with approximately 36,000 
deaths between 1990 to 1999 and 226,000 hospitalizations from 1979 to 2001. 
Symptoms associated with the flu typically emerge abruptly after an incubation 
period of 1 to 4 days, and symptoms resolve in 3to 7 days in uncomplicated cases, even 




the symptoms are cough, fever, respiratory symptoms, malaise, myalgias, sore throat, and 
rhinitis. Children may present with these symptoms and also may exhibit nausea, 
vomiting, and otitis media (Heymann, 2008). Because these respiratory symptoms are 
often clinically indistinguishable from other respiratory syndromes and viruses, accurate 
diagnosis and laboratory confirmation is critical for appropriate treatment choices to 
occur. Diagnosis is complicated by the varied and often nonspecific signs and symptoms 
of influenza. The primary methods used for diagnosis of influenza infection are viral 
culture, rapid diagnostic tests, reverse transcriptase-polymerase chain reactions, or 
clinical diagnosis without the laboratory testing based on sign and symptoms and current 
statistics of the influenza burden in the population for the time period. Each method has 
varied accuracy to predict the presence of the influenza virus; test sensitivity, specificity, 
and positive and negative predictive values, therefore, require careful data interpretation 
by qualified healthcare professionals. Point-of-care rapid testing can aid in the speed of 
diagnosing influenza and can assist clinical decision making for appropriate therapy and 
control measures (Heymann, 2008).  
Falsey, Murata, and Walsh (2007) studied the impact of rapid diagnosis testing 
and the management of adults who were hospitalized with influenza. A review of medical 
records over four flu seasons revealed rapid influenza testing leads to reduced antibiotic 
use in hospitalized patients. The results of this study found the positive influenza test was 
associated with modest withholding or discontinuing antibiotics; however, a significant 
portion of the test positive patients at low risk for bacterial infection continued to receive 




discontinue antibiotics in patients with negative chest x-rays and negative bacterial 
cultures, and two thirds of the respondents believed they would be (Falsey et al., 2007). 
Medical record review, however, found in practice that these physicians did not 
discontinue antibiotic use (Falsey et al., 2007). Physicians are concerned about secondary 
bacterial infections with an influenza diagnosis and the ability to distinguish concomitant 
bacterial or viral infections during peak seasons for respiratory illness (Falsey et al., 
2007). Even with sound medical evidence of no secondary or concomitant respiratory 
illness or disease, practitioners justified their choice to continue antibiotic use. 
Several studies have shown that diagnosis and treatment of influenza is not 
consistent among physicians. Linder et al. (2005) found that physicians prescribed 
inappropriate antibiotics to 26% of patients, and physicians prescribed antiviral 
medication to 19% of patients with an influenza diagnosis. This was similar to results 
from a study by Bonner et al. (2003) on decision making in a pediatric emergency room 
based on influenza testing information. This study found emergency room physicians, 
when blinded to the rapid influenza testing result, were more likely to perform more 
blood counts, blood cultures, urinalysis and cultures, and chest x-rays, prescribe 
antibiotics, and have patients stay longer in the emergency room with all the associated 
costs to the patient. In contrast, emergency room physicians who were aware of the 
positive influenza test result used less laboratory tests, antibiotics, and emergency room 
time in addition to prescribing antiviral medications more than those physicians who did 
not know the influenza test result. The findings of this study provided evidence that 




emergency room setting when they are made aware of influenza rapid testing results prior 
to seeing the patient for evaluation. This type of clinical management is the focal point of 
antimicrobial stewardship, which involves improving clinical outcomes while minimizing 
antibiotic use and its unintended adverse consequences. 
Antibiotic/Antiviral Stewardship 
Antimicrobial stewardship is defined as “coordinated interventions designed to 
improve and measure the appropriate use of antimicrobial agents by promoting the 
selection of the optimal antimicrobial drug regimen dosing, duration of therapy, and route 
of administration” (SHEA, IDSA, & PIDS, 2012, p. 323). 
Bartlett (2011) noted CDI and the crisis of antimicrobial resistance as two major 
health care challenges and one of the most pressing public health issues. At the heart of 
both of these two challenges is antimicrobial use and abuse (Bartlett, 2011). The CDC 
(2012b) noted that “good antibiotic stewardship is an important aspect of quality 
healthcare that prevents CDI” (p. 3). Inappropriate antimicrobial use can diminish the 
therapeutic benefit of the drug and facilitate the development of drug resistance (Moody 
et al., 2012). Antibiotic use is a major contributor to the spread of antimicrobial 
resistance, and broad-spectrum antibiotics can lead to diarrhea. “Clostridium difficile is 
the most common cause of antibiotic-associated diarrhea” (Olivo & Ranalli, 2013, p32). 
Hicks, Taylor, and Hunkler (2013) found among United States outpatients in 2010, 258 
million antibiotic prescriptions were written, 8.33 per 1,000 Americans or five antibiotic 




antimicrobial stewardship programs are complex. There are multiple points of care by 
healthcare workers and often require difficult behavior changes. 
An appropriate choice to treat influenza is antiviral medications. They can reduce 
the duration of influenza symptoms by one to almost three days and reduce complications 
that require the use of antibiotics (Linder et al., 2005). Additionally, antiviral use may 
decrease hospitalization and mortality. Linder et al. found the use of antiviral medications 
for management of influenza important, given influenza vaccine receipt and effectiveness 
can vary. The CDC states “antiviral medications are an adjunct to influenza vaccination 
and are effective when administered as treatment and when used for chemoprophylaxis 
after exposure to the influenza virus” (CDC, 2009, p. 2). The primary goal of 
antimicrobial stewardship is to improve clinical patient outcomes and minimize 
unintended adverse consequences due to inappropriate selection, dosing, and duration of 
these medication therapies. 
Antibiotic/Antiviral Stewardship and CDAD 
The incidence of CDAD before and after implementing antibiotic stewardship 
programs has been described by many studies across the United States and other 
countries, with similar results. The removal or reducing the use of an offending 
antimicrobial agent can result in decreased CDAD. The stewardship protocol of requiring 
infectious disease physician or pharmacist approval for prescriptions for most parenteral 
antibiotics brought about a significant and lasting reduction in CDAD incidence; a 47% 
decrease in all CDAD and 42% decrease in new cases in a hospital setting (Nuila, Cadle, 




attributable risks for CDAD may be due to the antimicrobial selected and overall 
frequency and of use in the population. This was more specifically found in a study by 
Gaynes et al. (2004) in a long term care (LTC) setting where two different but similar 
fluoroquinolones (gatifloxacin and levofloxacin) were used. The findings by Gaynes et 
al. described the use of gatifloxacin and clindamycin were associated with increased risk 
of CDAD, and in particular the increased number of days receiving gatifloxacin therapy; 
67% of the study patients with CDAD received gatifloxacin compared to 24% who 
received clindamycin. Increasing the duration of therapy of gatifloxacin significantly 
increased the attack rate and risk for CDAD. Clindamycin has historically been the 
second most frequently associated antimicrobial agent associated with CDAD (APIC, 
2013; Gerding, 2004).  A cost saving measure, formulary change, from levofloxacin to 
gatifloxacin had indeed coincided with an increase of CDAD among LTC residents, but 
when the gatifloxacin was substituted back to levofloxacin the rate of CDAD decreased 
(Gaynes et al., 2004). Similarly, Pear, Williamson, Bettin, Gerding, and Galgiana (1994) 
found the increased use and duration of clindamycin use was statistically associated with 
and epidemic strain of clindamycin resistant Clostridium difficile and by restricting 
clindamycin use, the associated epidemic pattern of CDI resolved, and there was a 
marked decreased in new cases of Clostridium difficile. In a contradicting case, Berild, et 
al. (2003) compared two similar hospitals in Norway for CDI in terms of antibiotic use 
and infection control practices. The researchers obtained point prevalence data of 
antibiotic associated diarrhea and antibiotic use from both facilities. Despite the 




reported. Interestingly, the study could lead the reader to surmise the decreased antibiotic 
use did not have an effect on CDI. The study data revealed there was a higher frequency 
of Clostridium difficile testing at this hospital, which consequently resulted in a higher 
reported incidence of CDI. The results of this study are confounding and may not actually 
correlate hospital antibiotic use and the reflected incidence of CDI, but an artifact of 
varied laboratory testing and reporting.  
The role of antibiotic induced Clostridium difficile diarrhea, infection, and colitis 
has been well documented, while the discrete use antivirals in the development of CDI 
has not. Colarian (1988) reported a case of Clostridium difficile colitis in a male patient, 
with a history of acquired immunodeficiency syndrome (AIDS), who had been treated 
with the antivirals acyclovir and azidothymidine (AZT), and had not received any 
antibiotics in the prior six months. A group of Clostridium difficile studies where the 
patients’ immune systems were compromised revealed use of antivirals, but did not 
specify antiviral use individually in the data analysis (Gellad et al., 2007; Gorschlüter et 
al., 200; Pulvirenti et al., 2002). In the study by Pulvirenti et al., antimicrobials-- defined 
as antivirals, antifungal, and antibacterial agents-- were studied for development of CDI 
in human immunodeficiency virus (HIV) patients. The study did not provide detailed 
names of the antivirals included nor did it analyze the use of antivirals as an individual 
variable. Gellad et al. studied the severity of CDAD in solid organ transplant patients and 
specified exposure to antivirals as a variable; the study did not find any statistically 
significant differences in development of severe colitis among the study groups of 




characteristic variable, but did not analyze antiviral use individually. This was also noted 
in a study by Gorschlüter et al., where the specific oral antiviral, acyclovir, was used 
among study patients. Antiviral class use was an aspect considered in a specific, large 
outbreak study by Muto et al., (2005), but was not independently associated with CDI. 
 Antimicrobial-induced diarrhea and development of CDI are serious 
complications of patient medical management and requires thoughtful antimicrobial 
selection in the choice to treat any infecting pathogen. 
History and Changing CDI Epidemiology 
Bartlett (2011) reviewed the 30 year history of CDI and indicated in the late 
1970s, antibiotic-associated colitis could occur from almost any antibiotic with an 
antibacterial spectrum of activity, but primary offenders were clindamycin and broad-
spectrum antibiotics. Cephalosporins, clindamycin, and fluoroquinolones have a higher 
risk for causing disease due to the antibiotic’s ability to disrupt lower intestine normal 
flora (APIC, 2013). Bartlett noted for the first 25of the 30 year time period, CDI was a 
severe complication of antibiotic use that could be life threatening, but the mortality rates 
were low. Bartlett, 2011; Elixhauser and Jhung, 2008 reported a surge of CDI cases 
during the years 2001 to 2005. Not only was there a 102% increase in four years, but also 
a substantial increase in attributable mortality. Noticing among the increase in CDAD 
deaths and that 80% of these deaths occur in acute care hospital settings, Zilberberg, 
Shorr, and Kollef (2008) further found there was an increase in CDAD hospitalizations 
for the years 2000 to 2005. This surge in the number of cases and increased mortality has 




strain (Bartlett, 2011). The emergence of this strain has been thought to be due to the 
developed resistance of Clostridium difficile to fluoroquinolones which had been widely 
used, as the NAP1 strain was uncommon in historic strains (Bartlett, 2011). The NAP1 
strain hallmark is higher toxin production, which may account for the increase in severity 
of outcomes and mortality. Concurrent with this hyper-virulent epidemic strain, fully 
identified as BI/NAP1/027, CDI prevalence more than doubled in hospitalized patients 
(Tabak et al., 2013). The highest rates of CDI occurred among persons 65 years and 
older, with over two-thirds of the patients with CDI being elderly (APIC, 2013; 
Elixhauser & Jhung, 2008). Females had higher rates of CDI related hospital stays than 
males, and new populations previously thought to be low risk have emerged: healthy 
peripartum women, children and healthy adults with minimal or no recent exposure to 
healthcare settings (APIC, 2013). An additional change in CDI epidemiology has been 
noted in the regional incidence from review of U.S. hospital discharge data. Elixhauser 
and Jhung (2008) found “the Northeastern rate was two times higher than the West, 
which had the lowest rate. The rates in the Midwest and South were 69 percent and 42 
percent higher than the Western rate, respectively” (p. 2). The purpose of this quantitative 
study was to examine the temporal progression of CDI incidence and take into account 
meaningful data elements, such as geographic regional differences. 
CDI Seasonality 
Seasonal patterns for CDI have been noted by Jagai et al. (2007), in the United 
States a pattern that peaks in mid-March for all age groups. In addition, Polgreen et al. 




occurring in March. In contrast, Bruckhardt, Friedrich, Beier, and Eckmanns (2008) 
found trends of CDI did not follow obvious seasonal trends like other enteric diseases 
such as Salmonella species, Rotavirus, and Norovirus, rather an overall increase in CDI 
incidence. In another case, a study conducted by Larang, Repayo, Chan and Murillo 
(2011) described Clostridium difficile testing for the year of 2009 and found a bimodal 
distribution for ages 71 to 75 and 1 to 5 years, along with a bimodal seasonal distribution 
of positive tests that peaked in March and November. R. S. Larang clarified that this 
Clostridium difficile study did not consider the influenza season, but indicated it was 
interesting the age groups in the study are the same as those most affected by influenza 
(personal communication, July 18, 2011). The significance of this study is the data year 
used was 2009, this was the year of the novel influenza A (H1N1) that showed very 
unique activity and distinct bimodal peaks of influenza activity, in contrast to the typical 
seasonal influenza single peak in late fall/early winter in the United States. The 
2008/2009 seasonal influenza peak was January 2008 through March 2009, with the 
second novel influenza A (H1N1) activity starting and peaking quickly in late April to 
early May 2009. The influenza A (H1N1) activity continued through June 2009. The A 
(H1N1) strain co-circulated, and in many U.S. regions it never completely diminished 
when the seasonal influenza again emerged in September lasting through late December 
2009 (CDC, 2012a). Accordingly, Polgreen et al. (2010) found using time-series 
methodology while reviewing regional and national level data revealed peak CDI 




analysis performed for the study implied the seasonal variation was included because the 
typical influenza season occurs within each year and recurs periodically year after year.  
Summary 
The literature review I presented in this chapter provided some historic and 
epidemiologic background information of influenza and CDI. Additionally, the concept 
of antimicrobial stewardship and the factors driving the need for this strategy where 
identified. The literature offered evidence of the well known, key risk factor of antibiotic 
exposure contributing the development of CDAD. Also, the literature revealed the key 
population characteristics that was used to select my study sample population. 
Moreover, the literature provided insight to the dependent and independent 
variables. The study basis to suspect that seasonal influenza may be linked to an increase 
in the subsequent development of CDI was revealed in the literature. However, lacking in 
the literature are studies to analyze aggregate data and support an influenza and CDI link 
due to monthly receipt of antibiotics/antivirals in hospitalized patients. The literature 
reviewed does provide justification to test the proposed hypotheses and analyze the 
association of the independent variables and the one dependent variable using multiple 
logistic regression. In Chapter 3, I will describe the research method and design. Also, the 
study variables will be discussed and the context of the intended data elements to be 




Chapter 3: Research Method 
The purpose of this study is to address the use of antiviral/antibiotic usage during 
the influenza season and the incidence of CDI. In this chapter, I discuss the testing of the 
hypotheses that explain an association between the use of prescription antivirals or 
antibiotics to predict CDI within 60 days of discharge in patients who have been 
hospitalized for influenza. A retrospective, observational design was used to describe and 
analyze the relationship between the incidence of CDI development and the related 
variables of antiviral/antibiotics among patients hospitalized for influenza. The chapter is 
divided into sections of research design, population and setting samples, variable 
descriptions, data analysis plan, threats to validity, and ethical concerns. 
Research Design 
In this study, I describe and analyze retrospective observations of data from a 
proprietary, laboratory, and pharmacy based system from a cohort of hospitals. The 
retrospective nature of this research was chosen based on the timing of the influenza 
seasons for the study years. This observational study provides information to explore the 
cause of CDI incidence and determinants.  
A retrospective observational cohort design was chosen due to the novelty of the 
relationship between the variables that had not previously been documented in the 
literature reviewed. It seemed reasonable to begin the study inquiry using an 
observational study approach. The benefits of using this type of observational study 




using fewer resources compared to a logistically challenging prospective experimental 
design (McPherson & Bunker, 1991). 
The limitation of using a retrospective cohort study compared to a prospective 
experimental study is detailed information on exposure and confounders may not be 
controlled for in the data collection process (Aschengrau & Seage, 2003). Despite this 
recognized limitation, the observational design was used for the novel hypotheses with 
the rationale the study may not require the resources for an experimental design. 
An observational design was chosen over a cross-sectional design due to cross-
sectional observations are based on a single point in time (Babbie, 2007). The influenza 
and development of Clostridium difficile data in this study lends itself to the time-related 
option of observations over a longer period of time. The best way to study changes over 
time is to utilize a longitudinal study (Babbie, 2007). Therefore, this retrospective cohort 
study was based on data collected over the influenza seasons time frame. 
Population and Sampling 
Study Population 
The study population for this research consisted of U.S. hospitals that subscribe to 
the surveillance and pharmacy system known as MedMined Surveillance Advisor, a 
division of CareFusion (CareFusion, 2013). There are approximately 400 hospitals that 
subscribe to the MedMined electronic surveillance module and about 30%, representing 
approximately 125 hospitals, subscribe to the electronic pharmacy module known as 




services and pay a monthly fee. The hospital demographic using MedMined services are 
primarily short-term acute care hospitals across the United States.  
For this study, long term care, rehabilitation, and children’s hospitals were 
excluded from sampling. Sampling was from acute care hospitals and adult patients. In 
long term hospital and rehabilitation settings, patients are often treated as residents and 
have healthcare issues and disease management that are not considered acute. A 
convenience sample was used taking into account that the highest rates of CDI occur 
among persons 65 years and older, with over two-thirds of the patients with CDI being 
elderly, and females having higher rates of CDI related hospital stays than males (APIC, 
2013; Elixhauser & Jhung, 2008). It was noted in Chapter 2 that new populations 
previously thought to be low risk populations for CDI have emerged: healthy peripartum 
women, children, and healthy adults with minimal or no recent exposure to healthcare 
settings (APIC, 2013). Healthy, peripartum women and healthy adults with minimal or no 
recent exposure to healthcare settings were not excluded. For this study, children were 
excluded because the respiratory syndromes seen in the very young during the typical 
seasonal influenza season often manifest as RSV (Nelson & Williams, 2007). The CDC 
(2010) reported that during the influenza season, there are more outpatient visits in 
children and annual hospitalization rates for lab confirmed influenza decrease with 
increasing age. Additionally, children are often less exposed to antibiotics in terms of 
years and the antibiotic choices selected by pediatricians and neonatologists. Therefore, 
data for lab confirmed influenza with inpatient antibiotic utilization among children 




The changes in CDI epidemiology noted in the regional incidence from a review 
of U.S. hospital discharge data was taken into account by sampling more in the 
Northeast, Midwest, and South than the Western portion of the United States (Elixhauser 
& Jhung, 2008). The United States is divided into four main regions by the U.S. Census 
Bureau for population survey and registration data. These four regions are designated by 
the Census Bureau as Northeast, Midwest, South, and West and were used for this study 
data collection (U.S. Department of Commerce, 2013).  
The exact peak and year of seasonality incidence was determined using CDC’s 
FluView tracking system (CDC, 2012a). Additionally, seasonal incidence was viewed in 
the MedMined graphing feature for each hospital’s source specific data. The graphing 
feature allows for visualization of the epidemiologic curve based on the frequency of 
positive microbiologic isolates for influenza with the axis’ of number of isolates and 
calendar week. Based on this graph, the peak weeks of the season can easily be identified 
and further verified with the CDC FluView system of reports geographic incidence 
density. This provided time series analysis and insight to seasonal variation.  
Sample Size 
In order to estimate the minimum sample size required to confidently accept the 
results of the analysis, sample size tables for logistic regression were consulted (Hsieh, 
1989). The literature indicated the probability of a CDAD diagnosis within 60 days of 
hospitalization is approximately 12 (Rodemann, Dubberke, Reske, Seo, & Stone, 2007). 




deviation above the mean using a one-tailed test with a significance of 0.5 and a power of 
80%, a minimum of 146 participants was needed (Hseih, 1989).  
Variable Descriptions 
For this study, the measures collected from each hospital and analyzed for 
possible association included the of diagnosis and/or positive test for influenza and the 
independent variables of delivery of antiviral/antibiotics during the patient’s 
hospitalization as well as the dependent variable of positive test or diagnosis of CDI. In 
this study, I used all eligible adult and elderly patients with the operational definition of 
adult, 18 to 64 years old, and elderly defined as age 65 years and older. This definition 
was consistent for age groups used and defined in the Healthy People 2020 objectives for 
improving health (U.S. Department of Health and Human Services, 2020).  
The dependent variable of a diagnosis of CDI is defined as a positive laboratory 
test for Clostridium difficile using standard laboratory methodology such as, toxin assay, 
polymerase chain reaction (PCR), or antigen tests. The definition of CDI included the 
diagnosis field listing terms CDI, Clostridium difficile infection, or Clostridium difficile.  
The study population was pulled from hospitalized patients with influenza. The 
definition of influenza included the diagnosis field listing terms of influenza, flu, and any 
flu specific types such as influenza A, B, and H1N1. The diagnosis of influenza is also 
defined as a positive laboratory test for influenza using standard laboratory methodology 
such as viral culture, serology, rapid diagnostic (antigen) testing, reverse transcription 




For this study, the antimicrobial independent variables were use of antibiotics and 
antivirals among the patient population. Garey (2011) described that nearly all antibiotics 
have been implicated as the causative agent in the development of CDI. Broad spectrum 
antibiotics and certain antibiotic classes such as cephalosporins, clindamycin, and 
fluoroquinolones are most highly implicated (Bartlett, 2011). Therefore, based on the 
literature, data extraction to determine if antimicrobials were used was performed, and 
use of any antimicrobial without categorization was included for this variable definition 
(Bartlett, 2001; Garey, 2011). Several studies provided insight that physicians often 
prescribe antibiotics along with antivirals to treat influenza (Bonner et al., 2003; Falsey et 
al., 2007; Linder et al., 2005). In particular, among adult patients, Linder et al. found 26% 
of patients diagnosed with flu were prescribed antibiotics not associated with an 
antibiotic appropriate diagnosis, meaning excluded people whose diagnosis could 
credibly include a bacterial infection where antibiotic therapy is appropriate treatment. To 
illustrate the impact, Linder et al. found between 2 and 4 million people seek medical 
care for the flu every year, and this calculates into 500,000 to 1 million inappropriate 
antibiotic prescriptions. Bacterial complication rates from the flu among older adults have 
not been studied fully and there lacks data to support antibiotic use as a method of 
preventing influenza related complications (Bonner et al., 2003). Additionally, studies 
have shown that diagnosis and treatment of influenza is not consistent among physicians 
(Bonner et al., 2003; Linder et al., 2005).  
In the United States, there are currently four licensed prescription antiviral agents 




2011). For this study, the use of any antiviral, including the four antiviral agents used to 
treat influenza, was included for this independent variable.  
The study population was hospitalized patients with influenza. The definition of 
influenza included the diagnosis field listing influenza terminology and/or a positive 
laboratory test for influenza. Within this population, the dichotomous dependent (CDI) 
and independent variables (antibiotics use, antiviral use, antiviral and/or antibiotic use) 
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Data Analysis Plan 
The data were from a cohort of hospitals that use CareFusion MedMined services. 
In this study, I used proprietary surveillance data that includes patient level information 
such as diagnostic laboratory test results, ADT, and prescribed medications such as 
antimicrobials and antivirals. Microbiology data for the dependent outcome variable of 
Clostridium difficile or diagnosis of CDI and the independent variables of 
antibiotics/antivirals use among patients hospitalized with a positive test or diagnosis for 
influenza was analyzed using SPSS (Version 22.0). The web based tool owned within 
CareFusion MedMined to perform such a query is the Virtual Surveillance Interface 
(VSI). The VSI allows the end user to perform specific data extraction by creating 
customized, specific reports based on search criteria such as influenza and Clostridium 
difficile and inpatient versus outpatient criteria. For this study, a report was written and 
used to query based on these organisms and inpatient categorization. The patients 
identified from this inquiry were then be further queried for diagnosis details and 
medication delivery. 
These patient data were queried and abstracted by looking up the indvidual patient 
level details using the patient name or medical record number (MRN) and searching the 
patient gender, date of birth, and diagnosis data field for a diagnosis of influenza, and 
CDI. For the independent variables of delivery of antiviral/antibiotics, a patient level 
inquiry was performed from the Patient Event Advisor portion of the MedMined 




functions and running a query for the associated hospitalization admission time frame and 
the prescribed antiviral/antibiotics given. 
After the data were collected, they were exported and populated into a 
spreadsheet to categorize the data elements and details. To protect the identity of the 
patient name and identifiable MRN, a new spreadsheet was created and random numbers 
assigned. This random number assignment allowed from this point forward to represent 
each study subject. From this spreadsheet, the variables were coded and formatted in 
preparation for the data analysis.  
Before proceeding, a test of the assumptions of the multivariate analysis was 
performed. Logistic regression was used to answer both the association and prediction 
hypotheses and research questions. Multivariate analysis was performed using logistic 
regression to test the hypotheses and determine whether or not the use of 
antiviral/antibitotics is associated and predictive of CDI among hospitalized influenza 
positive patients. For the first two hypotheses, each independent variable was tested 
individually to determine statistical significance. 
 Research Question 1: Is there a relationship between use of prescription antivirals 
and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza? 
 H01: There is not a statistically significant association between use of prescription 





 Ha1: There is a statistically significant association between use of prescription 
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
The first hypothesis of there is not a statistically significant association between 
use of prescription antivirals and CDI within 60 days of discharge in patients who have 
been hospitalized for influenza was tested using logistic regression. The dependent 
outcome variable of Clostridium difficile or diagnosis of CDI and the independent 
variable of antiviral use among patients hospitalized with positive test or diagnosis for 
influenza. A p value of 0.05 was used to determine significance. If the results yeild a p 
value less than 0.05, the null hypothesis was rejected and the alternative hypothesis was 
accepted. 
Research Question 2: Is there a relationship between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza? 
 H02: There is not a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
 Ha2: There is a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
The second hypothesis of there is not a statistically significant association 




who have been hospitalized for influenza was tested using logistic regression. The 
dependent outcome variable of Clostridium difficile or diagnosis of CDI and the 
independent variable of antibiotic use among patients hospitalized with positive test or 
diagnosis for influenza. A p value of 0.05 was used to determine significance. If the 
results yeild a p value less than 0.05, the null hypothesis was rejected and the alternative 
hypothesis was accepted. 
Research Question 3: Does the use of prescription antivirals and/or prescription 
antibiotics predict CDI within 60 days of discharge in patients who have been 
hospitalized for influenza? 
 H03: The use of prescription antivirals and/or prescription antibiotics does not 
predict CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
 Ha3: The use of prescription antivirals and/or prescription antibiotics does predict 
CDI within 60 days of discharge in patients who have been hospitalized for influenza. 
The third hypothesis was tested using multiple logistic regression analysis. The 
use of prescription antivirals and/or prescription antibiotics does not predict CDI within 
60 days of discharge in patients who have been hospitalized for influenza. The dependent 
outcome variable of Clostridium difficile or diagnosis of CDI and the independent 
variables are antibiotics and/or antivirals use among patients hospitalized with positive 
test or diagnosis for influenza. The independent variables of either antibiotics, antivirals, 
or both were used in the regression analysis for the third hypothesis. Coefficient size and 




not predictive of CDI then the null hypothesis was rejected. The positive or negative 
value of each coefficient was analyzed to determine acceptance of the alternative 
hypothesis. 
Threats to Validity 
The potential threat to internal validity that may arise from this study could occur 
in the sample selection. Study subjects could have medical or physical characteristics that 
may predispose them to certain outcomes or being more susceptible to disease. This type 
of detailed data is not in the proprietary data base; therefore, I was unaware of these 
details. To account for this threat, use of random selection will increase the probability 
that these characteristics will be evenly distributed in the patient study subjects selected 
(Creswell, 2009). A potential threat to external validity is the sample population being 
only selected from hospitals who subscribe to use of CareFusion MedMined services. 
Because this data set only contains a fraction of the all U.S. hospitals, I may not be able 
to generalize the results to patient populations in other hospitals. To account for this 
threat, research findings will have to restrict claims about other hospitalized patient 
populations which the results cannot be generalized. 
Ethical Concerns  
This study, I did not use human participants directly, but used individual health 
information from hospitalized patients with all personal identifiers removed. Data 
confidentiality has been described above using a random number system after data 
extraction. Protection of the raw data that contains patient names and medical records 




the research time period. No personal identifiable information will be reported in the 
research study, aggregate data will be reported. After the study is complete and the 
dissertation does not require further data review the data will be moved to a locked safe 
and maintained for five years before being shredded and destroyed. Data access will be 
limited to only me and my committee members, if deemed necessary for dissertation 
review and guidance. Procedures for data collection and handling were in accordance to 
the Walden University Institutional Review Board (IRB). The IRB application for study 
approval reference number is 02-10-14-0119262. 
The hospital patient level data within the study population has a business 
agreement that includes health insurance portability and accountability act (HIPAA) 
language for protection of the data that use MedMined services as a computerized 
healthcare vendor. The business agreement allows CareFusion MedMined Services to use 
de-identified data for publications and marketing purposes both internal and external to 
the company. For the purpose of this study and research access to the data related to the 
hospitals and individual patients contained therein will require authorization by 
CareFusion MedMined Services. (Appendix B)  
The study was carried out using secondary data from CareFusion MedMined 
Services and therefore access will be from a remote work environment. The office used 
for work is the same office used for research, just with different workstations and 
computers. This is a locked office with limited access. Working with CareFusion 
MedMined Services database involves using detailed confidential data and the work 





I used a retrospective, observational design to describe and analyze the 
relationship between the incidence of CDI development and the related variables of 
antiviral/antibiotics among patients hospitalized for influenza. The purpose of this study 
was to address the use of antiviral/antibiotic usage during the influenza season and the 
incidence of CDI using a proprietary laboratory based surveillance system of secondary 
data from a cohort of U.S. hospitals. 
 The data collected was used to test the hypotheses that explains a statistically 
significant association between use of prescription antivirals or antibiotics to predict CDI 
within 60 days of discharge in patients who have been hospitalized for influenza. The 
hypotheses were tested and analyzed using multiple logistic regressions. A detailed 




Chapter 4: Results  
The purpose of this study was to examine the use of antiviral/antibiotic usage 
during the influenza season and the incidence of CDI among hospitalized patients using a 
proprietary laboratory based surveillance system of secondary data from a cohort of U.S. 
hospitals. Three research questions with the according hypotheses were explored: 
 Is there a relationship between use of prescription antivirals and CDI within 60 
days of discharge in patients who have been hospitalized for influenza?  
 H01: There is not a statistically significant association between use of 
prescription antivirals and CDI within 60 days of discharge in patients who have been 
hospitalized for influenza. 
 Ha1: There is a statistically significant association between use of prescription 
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
Is there a relationship between use of prescription antibiotics and CDI within 60 
days of discharge in patients who have been hospitalized for influenza? 
H02: There is not a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
 Ha2: There is a statistically significant association between use of prescription 





Does the use of prescription antivirals and/or prescription antibiotics predict CDI 
within 60 days of discharge in patients who have been hospitalized for influenza?  
H03: The use of prescription antivirals and/or prescription antibiotics does not 
predict CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
 Ha3: The use of prescription antivirals and/or prescription antibiotics does predict 
CDI within 60 days of discharge in patients who have been hospitalized for influenza. 
 In Chapter 4, I examine the data collection details, population sampling, data 
analysis results with tables, and the research questions’ findings summarization.  
Data Collection 
Data were generated using a proprietary laboratory based surveillance system of 
secondary data from a cohort of U.S. hospitals. The initial steps to obtain the data set 
required a query of hospitals using both the CareFusion MedMined Surveillance Advisor 
module and Patient Event Advisor module from the total number of hospitals that 
subscribe. From the selected segment of hospitals meeting this criteria, custom, 
individual VSI reports were written for each site to query search criteria of inpatients 
with influenza and Clostridium difficile across time frames to incorporate the 60 days of 
discharge. Population data were extracted based on meeting the criteria of adult patient 
age and hospitalized with a postive test for influenza. Multiple years were queried to 
obtain data across many flu seasons using years 2005 to 2014. The years selected for each 
hospital’s VSI report was based on each individual site’s specific available data for 




been stored in the repository. This was also joined to the database utilization of the 
Patient Event Advisor module that houses the pharmacy portion of the patient records. 
The development of CDI within 60 days of discharge was based on the date listed in the 
database for the patient discharge timeframe and a positive laboratory test for Clostridium 
difficile.  
After the reports were generated, the sample population was selected. The 
population was randomly chosen without regard for gender. States in which hospitals 
were located were randomly dispersed within the census bureau regions. Patients who 
were selected into the population data set were then queried using the Patient Event 
Advisor module using their specific MRN and time frame of hospital admission. Specific 
pharmacy data were retrieved, and the data elements of antiviral and antibiotics 
prescribed and dispensed were gathered. The exact names of the antivirals and individual 
antibiotics were identified and logged for data analysis. The population selected was 
chosen and verified based on positive laboratory test for influenza and Clostridium 
difficile. Cases were coded according to the dichotomous dependent variable (0 = No 
CDI, 1 = Yes CDI). The independent variables of antibiotic use, antiviral use, and either 
antiviral use, antibiotic use, or both used were coded No = 0 and Yes = 1. The population 
selected was also logged according to the four census regions: Northeast, Midwest, 
South, and West. Data were assessed for missingness, reviewed for accuracy, and cleaned 
prior to entry into SPSS to perform regression testing.  
Although the number of hospitals that subscribe to the MedMined database is 




subscribed to use of both MedMined modules did not have complete data variables  
populated for this study. Hospitals that did not have data in both modules for the time 
year periods required for the study were not used, resulting in the final study sample 
frame of 25 hospitals. While this limitation was a factor for not achieving the large 
sample size, the final study population was 147 patients, which met the minimum sample 
size requirement to achieve 80% power. After reviewing the diagnosis field in the data 
set and finding it unreliable and inconsistently documented, it was deemed best to use 
results of a positive laboratory tests for the criteria of both influenza and Clostridium 
difficile to ensure accuracy and consistency in the data collection. 
Results 
Data were gathered from 147 participants and entered in to SPSS version 22.0 for 
Windows. Descriptive statistics were conducted to outline the sample demographics. 
Frequencies and percentages were calculated for gender and regional representation 
according to the United States Census Bureau regions. Means (standard deviations) and 
ranges were used to describe the central tendency and spread of ages within the sample.   
Of the 147 study participants, 117 (79.6%) participants received antibiotics, 106 
(72.1%) received antivirals, 130 (88.4%) received antibiotics and/or antivirals, and 17 
(11.6%) patients developed Clostridium difficile within 60 days of discharge. Out of the 
17 patients who developed CDI, 11 had received both antibiotics and antivirals, four had 
received antibiotics only, and two did not receive antibiotics or antivirals. 
The overall sample had an average age of 62.9 years (SD = 19.7), with a range 




from 36 to 91 years with an average age of 67.6 years (SD = 16.5), compared with the 
average age of 62.3 years (SD = 19.9) for participants who did not develop Clostridium 
difficile. In Table 2 the distribution of samples positive with Clostridium difficile by 
region, gender, age and antimicrobial receipt are presented. 
Table 2 
 
Clostridium difficile Positive Sample by Region, Gender, Age, and Antimicrobial Receipt 
(n=17) 
 























































































The participant geographic region sample revealed (n = 44, 29.9%) from the 
Midwest region, Northeast region (n = 42, 28.6 %), South (n = 33, 22.4%), and the West 
(n = 28, 19.0%). Next, each region was examined for frequency of Clostridium difficile. 
The highest percentages for regions from which multiple participants were gathered were 
the Midwest and Northeast. A total of 12 participants, six participants from the Midwest 




total of approximately 8% of the 147 participants. In the West region, three participants 
of the 147 total developed Clostridium difficile, representing 2.0%, and two participants 
of the 147 total developed Clostridium difficile, representing 1.4% from the South.   
Within the regions, six participants of the 44 total participants from the Midwest, 
13.6%, and six participants of the 42 from the Northeast, 14.2%, developed Clostridium 
difficile. Overall, approximately 28% from these regions were diagnosed within 60 days 
from discharge with CDI. In the West region, three of the 28 (10.7%), had Clostridium 
difficile diagnosis, and for participants from the South region, two of the 33 (6.1%) were 
diagnosed from this sample with Clostridium difficile within 60 days. 
The sample was approximately equally divided between males (n = 72, 48.9%) 
and females (n = 75, 51.0%). Males had a slightly higher rate of Clostridium difficile 
diagnosis than females for the sample (7.5% vs. 4.1%). Within the gender specific 
categories, male gender diagnosed with Clostridium difficile is 15.3% and female gender 
with Clostridium difficile is 8.0%. The categorical demographic frequency and 
percentages of the study participants for each region and gender are presented in Table 3 





Frequency for Sampled Gender and Regions and Percent With Clostridium difficile 
(N=147) 
 
Demographic n % 
    
Gender frequency   
 Male 72 48.9 
 Female 75 51.0 
Gender percent with Clostridium difficile   
 Male 11   7.5 
 Female 6   4.1 
Gender specific percent with Clostridium difficile   
 Male (n=72) 11 15.3 
 Female (n=75) 6   8.0 
    
Region frequency   
 Midwest 44 29.9 
 Northeast 42 28.6 
 South 33 22.4 
 West 28 19.0 
Region percent with Clostridium difficile   
 Midwest 6   4.1 
 Northeast 6   4.1 
 South 2   1.4 
 West 3   2.0 
Region specific percent with Clostridium difficile   
 Midwest (n=44) 6 13.6 
 Northeast (n=42) 6 14.2 
 South (n=33) 2   6.1 





Research Question 1 
Is there a relationship between use of prescription antivirals and CDI within 60 
days of discharge in patients who have been hospitalized for influenza? 
  H01: There is not a statistically significant association between use of prescription 
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
  Ha1: There is a statistically significant association between use of prescription 
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
To examine Research Question 1, a binary logistic regression was conducted with 
the use of prescription antivirals predicting instances of Clostridium difficile within 60 
days of discharge while controlling for age and gender. Results of the binary logistic 
regression were not statistically significant (χ
2
(3) = 3.38, p = .336, Negelkerke R
2
 = .05) 
indicating that age, gender, and the use of antivirals were not significant predictors of 
Clostridium difficile diagnosis within 60 days from discharge. Thus, the null hypothesis 
was retained and no further interpretations were made. Results of the binary logistic 
regression with antiviral use predicting Clostridium difficile within 60 days of discharge 





Binary Logistic Regression With Antiviral use Predicting Clostridium Difficile 60 Days 
After Discharge 
 
      95% CI 
Predictor B SE Wald χ
2
 p OR Lower Upper 
        
Antiviral use 0.52 0.81 0.42 0.52 1.69 0.34 8.28 
Age 0.02 0.02 1.16 .282 1.02 0.99 1.05 
Gender 0.61 0.56 1.21 .271 1.84 0.62 5.48 
Note. Female referent group.  
To examine the first regression model, the Hosmer Lemeshow test was used in 
conjunction with the classification table to determine the model’s fit. For this model, the 
Hosmer Lemeshow test did not indicate a significant difference between the final 
regression model and the observed data (χ
2
(7) = 6.80, p = .450). The classification table 
was examined to further detail the model fit that suggested that 88.3% of the participants’ 
placement in the outcome groups was accurately predicted. However, this may be due to 
the fact that the model consistently classified all participants into the larger group, which 
contained 88.3% of the sample. The nonsignificant predictors (p > .05 for each) indicated 
that the model could not use the independent variables to accurately classify participants 
into a group of Clostridium difficile within 60 days versus no Clostridium difficile within 





Classification Table for Antiviral Use as Examined in Research Question 1 
 
 Predicted  
Observed No CDI CDI within 60 days % Correct 
    
No CDI 128 0 100 
CDI within 60 days 17 0 0 
Note. Overall correct classification of 88.3%. 
 
Research Question 2 
Is there a relationship between use of prescription antibiotics and CDI within 60 
days of discharge in patients who have been hospitalized for influenza? 
H02: There is not a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
Ha2: There is a statistically significant association between use of prescription 
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized 
for influenza. 
To examine Research Question 2, a binary logistic regression was conducted with 
the use of prescription antibiotics predicting instances of Clostridium difficile within 60 
days of discharge while controlling for age and gender. Results of the binary logistic 
regression were not statistically significant (χ
2
(3) = 3.75, p = .290, Negelkerke R
2
 = .05) 
indicating that age, gender, and the use of antibiotics were not significant predictors of 
Clostridium difficile diagnosis within 60 days from discharge. Thus, the null hypothesis 




regression with antibiotic use predicting Clostridium difficile within 60 days of discharge 
are presented in Table 6. 
Table 6 
Binary Logistic Regression With Antibiotic Use Predicting Clostridium Difficile 60 Days 
After Discharge 
 
      95% CI 
Predictor B SE Wald χ
2
 p OR Lower Upper 
        
Antibiotic use -0.52 0.56 0.85 .357 0.60 0.20 1.79 
Age 0.02 0.01 1.10 .295 1.02 0.99 1.04 
Gender 0.78 0.55 2.02 .155 2.19 0.74 6.42 
Note. Female referent group.  
To examine the second regression model, the Hosmer Lemeshow test was used in 
conjunction with the classification table to determine the model’s fit. For this model, the 
Hosmer Lemeshow test did not indicate a significant difference between the final 
regression model and the observed data (χ
2
(7) = 1.97, p = .961). The classification table 
was examined to further detail the model fit which suggested that 88.3% of the 
participants’ placement in the outcome groups was accurately predicted. However, this 
may be due to the fact that the model consistently classified all participants into the larger 
group, which contained 88.3% of the sample. The nonsignificant predictors (p > .05 for 
each) indicated that the model could not use the independent variables to accurately 
classify participants into a group of Clostridium difficile within 60 days versus no 








Classification Table for Antibiotic Use as Examined in Research Question 2 
 
 Predicted  
Observed No CDI CDI within 60 days % Correct 
    
No CDI 128 0 100 
CDI within 60 days 17 0 0 
Note. Overall correct classification of 88.3%. 
 
Research Question 3 
Do the use of prescription antivirals and/or prescription antibiotics predict CDI 
within 60 days of discharge in patients who have been hospitalized for influenza? 
H03: The use of prescription antivirals and/or prescription antibiotics does not 
predict CDI within 60 days of discharge in patients who have been hospitalized for 
influenza. 
Ha3: The use of prescription antivirals and/or prescription antibiotics does predict 
CDI within 60 days of discharge in patients who have been hospitalized for influenza. 
To examine Research Question 3, a binary logistic regression was conducted with 
the use of prescription antivirals or antibiotics predicting instances of Clostridium 
difficile within 60 days of discharge while controlling for age and gender. For this 
regression, the variable of antiviral or antibiotic use was coded such that 0 = neither 
antibiotic nor antivirals used, and 1 = either antibiotics, antivirals, or both used. Results 
of the binary logistic regression were not statistically significant (χ
2
(3) = 3.07, p = .382, 
Negelkerke R
2
 = .04) indicating that age, gender, and the use of antivirals or antibiotics 




discharge. Thus, the null hypothesis was retained and no further interpretations were 
made. Results of the binary logistic regression with antiviral and antibiotic use predicting 
Clostridium difficile within 60 days of discharge are presented in Table 8. 
Table 8 
Binary Logistic Regression With Antibiotic and/or Antiviral Use Predicting Clostridium 
Difficile 60 Days After Discharge 
 
      95% CI 




p OR Lower Upper 
        
Antiviral and/or Antibiotic 
use 
-0.32 0.83 0.15 .701 0.73 0.14 3.72 
Age 0.02 0.01 1.13 .287 1.02 0.99 1.04 
Gender 0.75 0.55 1.84 .175 2.12 0.72 6.29 
Note. Female referent group.  
To examine the third regression model, the Hosmer Lemeshow test was used in 
conjunction with the classification table to determine the model’s fit. For this model, the 
Hosmer Lemeshow test did not indicate a significant difference between the final 
regression model and the observed data (χ
2
(8) = 5.49, p = .705). The classification table 
was examined to further detail the model fit which suggested that 88.3% of the 
participants’ placement in the outcome groups was accurately predicted. However, this 
may be due to the fact that the model consistently classified all participants into the larger 
group, which contained 88.3% of the sample. The non-significant predictors (p > .05 for 
each) indicated that the model could not use the independent variables to accurately 
classify participants into a group of Clostridium difficile within 60 days versus no 







Classification Table for Use of Antivirals and/or Antibiotics as Examined in Research 
Question 3 
 
 Predicted  
Observed No CDI CDI within 60 days % Correct 
    
No CDI 128 0 100 
CDI within 60 days 17 0 0 
Note. Overall correct classification of 88.3%. 
 
Summary of Results 
 Three logistic regressions were conducted to determine a possible relationship 
between the use of antiviral or antibiotic medication with development of Clostridium 
difficile within 60 days of discharge from the hospital while controlling for the effect of 
gender and age. Results of the first logistic regression indicated there was no impact of 
antiviral use on development of Clostridium difficile within 60 days of discharge. Results 
of the second logistic regression indicated there was no impact of antibiotic use on 
development of Clostridium difficile within 60 days of discharge. Results of the final 
logistic regression examined cases of antiviral and/or antibiotic use and indicated there 
was no statistically significant impact of either medication on development of 
Clostridium difficile within 60 days of discharge. 
 In Chapter 5 the study findings will be examined and interpreted further to 
provide comparisons to the literature review, analyze the findings in the context of the 




findings and limitations, and explore the study’s impact for social change and 




Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of the study was to to examine the temporal progression of CDI 
incidence and the possible influence that the seasonal variation of influenza and antibiotic 
and antiviral use has on the incidence of CDI. An enhanced understanding could be 
determined about the relationship of CDI and seasonal influenza as well as the 
role/influence of antibiotic use and selection. The study’s significance may be to further 
contribute to the growing body of knowledge of the implications that antibiotic  use has 
on CDI. In this study, I examined if the overuse and/or inappropriate use of antibiotics 
has an impact on the development of CDI during seasonal disease outbreaks of influenza.  
Three logistic regressions were conducted to determine the relationship between 
the use of antiviral or antibiotic medication with development of Clostridium difficile 
within 60 days of discharge from the hospital while controlling for the effect of gender 
and age. The first logistic regression results indicated there was no impact of antiviral use 
on development of Clostridium difficile within 60 days of discharge. Next, the second 
logistic regression indicated there was no impact of antibiotic use on development of 
Clostridium difficile within 60 days of discharge. Finally, the third logistic regression 
results indicated when cases of antiviral and/or antibiotic use were examined, there was 
no statistically significant impact of either medication on development of Clostridium 
difficile within 60 days of discharge. 
Interpretation of the Findings 
The data from this study resulted in a representative population based on the 




and older, with over two-thirds of the patients with CDI being elderly (APIC, 2013; 
Elixhauser & Jhung, 2008). This study population’s average age was 62.9 years old, with 
an age range of 19 to 101. Among the influenza positive study population who developed 
Clostridium difficile, the average age was  67.6 years old, similar to the results by APIC, 
2013 and Elixhauser and Jhung, 2008.  
Additionally noted by Elixhauser and Jhung are changes in CDI epidemiology 
regional incidence based on a review of United States hospital discharge data, finding the 
Northeastern rate was 2 times higher than the West, which had the lowest rate. The 
frequencies in the Midwest and South were 69% and 42% higher than the West 
frequency, respectively (Elixhauser & Jhung ,2008). I found a slight difference in the 
highest percentage of Clostridium difficile coming from the Midwest (4%) and Northeast 
(4%) equally and the West (2%) was slightly higher than the South (1%), which includes 
taking into account the study’s design of more sampling in the Northeast, Midwest, and 
South than the West. Although rates of CDI related hospital stays are higher in females 
than males (APIC, 2013), this study revealed the incidence of CDI within 60 days of 
discharge among hospitalized patients with the flu nearly double in males (7%) versus 
females (4%). The study population was nearly equal sample population of males versus 
females. This difference in gender incidence was in contrast to cited findings (APIC, 
2013) and therefore suggests the need for further study.  
As described in Chapter 2, using the wheel model of man-environment 
interactions framework, the study increased understanding determinents of CDI, seasonal 




adults (host) at the center of the three sections of the environment illustrated the role in 
disease development of CDI as many medical decisions start with the individual. The 
development of influenza is based on the lack of vaccine receipt, naïve host, or a vaccine 
mismatch due to a differing circulating/novel influenza strain (CDC, 2009). This section 
weighs heavy in the biological section, as does receipt of a good strain match of vaccine 
for influenza prevention. Additionally, there can be biological factors of a dose-response 
relationship in the development of influenza with the occurrence of influenza based 
exposure to the associated influenza strain and the proportion of vaccine match for those 
who received it (CDC, 2009; Glezen, 2006). Admission to the hospital or need to seek 
medical intervention for influenza is in the social and biological sections. This can have 
social constructs of individual, family, or cultural groups influencing the health seeking 
behavior and decisions to seek treatment. The study database was not accessible for 
determinants of reasons for hospitalization or social constructs to seek care. The physical 
environment includes exposure to Clostridium difficile spores in the physical hospital 
environment and the social aspects include if the physician prescribes antibiotics that may 
alter the host gut to develop CDI as well as the host request and acceptance of antibiotics. 
Although this is true, the environmental factors that influenced CDI development were 
not explored in this study. The physican’s desire to use antibiotics may be based on the 
need to provide comprehensive coverage for all upper and lower respiratory conditons 
without a clear etiology, not having or waiting for influenza testing results prior to 
administration of antibiotics for bacterial infections versus antivirals for viral infections 




patient, or maintain patient satifaction as they request medications (Bonner et al., 2003; 
Linder et al., 2006). Social aspects of care for the study population by the medical 
providers would greatly influence this portion of the wheel. This area of the physicians’ 
use of antibiotics in the face of a positive influenza result could not be explored fully due 
to database limitations; it was not a full medical record with access to documentation of 
coinfection or other signs and symptoms.  
There were clear cases of study individuals who did not receive any antibiotics or 
antivirals and cases who received antibiotics only without antivirals despite the fact they 
were test positive for influenza. Antivirals are the appropriate choice to treat influenza. 
They can reduce the duration of influenza symptoms by 1 to almost 3 days and reduce 
complications that require the use of antibiotics (Linder et al., 2005). Additionally, 
antiviral use may decrease hospitalization and mortality. Linder et al. found the use of 
antiviral medications for management of influenza important, given influenza vaccine 
receipt and effectiveness can vary. The study data demonstrated within this hospital 
cohort and sample population that the recommended administration of antiviral 
medication was not consistent among influenza positive patients. Of the 147 study 
participants, 117 participants received antibiotics, 106 received antivirals, and 130 
received antibiotics and/or antivirals. Each of the study participants had laboratory 
evidence of positive influenza; with this diagnostic certainty, the sample population 
should have all received antiviral medication according to practice recommendations 
(ACIP, 2011). The study data confirmed findings in the literature (Falsey et al., 2007; 




diagnosis and antibiotic use continued during the hospital stay. Although it is true that 
there were database limitations of no access to indicators of antibiotic use that could be 
found in the full medical record, documentation of coinfection, or other signs and 
symptoms, the data could be extrapolated based on the literature that physicians 
prescribed inappropriate antibiotics about 26% of the time (Linder et al., 2005). 
Additionally, this study illustrated the evidence that physicians do not alter their clinical 
decisions for treatment of influenza when positive results are readily available and treated 
with antibiotics. This confirmed the findings of Falsey et al. that with sound medical 
evidence, practitioners justify the choice to continue antibiotic use and supported the 
work by Linder et al. that physicians prescribe inappropriate antibiotics to patients with 
an influenza diagnosis. The study data contradicted the findings of Bonner et al. (2003) 
that physicians who have knowledge of influenza test results used less antibiotics and 
prescribed more antiviral medications. In this study, I found the physicians had evidence 
of positive influenza test results documented in the microbiology data on each individual 
patient. The lab tests were ordered, testing was performed in the clinical laboratory, and 
the results were available for physicians to utilize while making medical decisions for 
care and treatment. Based on the lab test results, the need to order and dispense 
medication, such as antivirals and antibiotics, may be indicated. The study population of 
147 participants were all positive for influenza, yet 117 (79.6%) participants received 
antibiotics, 106 (72.1%) received antivirals, 130 (88.4%) received antibiotics and/or 
antivirals and 17 (11.6%). The 17 patients who developed Clostridium difficile within 60 




antibiotics only and two did not receive antibiotics or antivirals. Therefore, my study 
findings indicate more antibiotics and less antivirals are prescribed when physicians have 
knowledge of influenza test results.  
 
Limitations of the Study 
The data used in this study were collected for patient care and not for research. 
The study was limited to the association of data and did not allow for a cause and effect 
inference because I did not directly collect the data used for this research study. An 
observational, nonexperimental design limits the interpretation of the results (McPherson 
& Bunker, 1991). Use of these data for the purpose of a research study revealed 
limitations but did allow for data analysis within the database limitations to answer the 
research questions. Additionally, the database did not include signs and symptoms of 
patients’ medical conditions or chief complaints, detailed documentation of underlying 
medical conditions that can be exacerbated by influenza infection, or queried for 
secondary infections, coinfections, or complications from influenza, such as pneumonia. 
With this in mind, sign and symptom information, along with documentation of 
coinfections and complications from influenza, did not allow me to extrapolate definitive 
clinical implications for the use of antibiotics in the sample population hospitalized with 
positive influenza. Moreover, documentation or knowledge of influenza and 
pneumococcal vaccine receipt was limited to only the data recorded in the medication 
module; therefore, vaccine receipt from anywhere other than the hospital’s dispensing 




vaccines given elsewhere to remain unknown. The research study did not use vaccine 
reciept as a variable. Extraction of the available data set used for the research was limited 
to the hospital’s geographic location, laboratory results, admitting diagnosis, medication 
orders and dispensing, patient age, and gender.  
Another study limitation was the sample size. As indicated by the calculation 
described in Chapter 3, the study sample collected would be sufficient; however, this 
depended on the distribution of the outcome and size of the effect. The study revealed 
few CDI, so the lack of significant findings may have been influenced by two factors. 
The effect sizes were small and therefore impacted the study power. 
I used a proprietary database from a set of hospitals that pay for the electronic 
surveillance system and pharmacy modules. The database used was taken at face value 
for data accuracy from the hosted hospital documentation and electronic results. Paid 
services of electronic surveillance and pharmacy medication modules made this group of 
hospitals unique in terms of their commitment to infection prevention data collection and 
antimicrobial monitoring. As a result, increased sampling bias may have been introduced 
from this database being used as a research cohort than that seen in random sampling, 
indicating that the sample may not have been representative of the United States 
population.  
Recommendations  
Findings from this research revealed the need to further study populations of 
influenza positive patients. Specifically, future studies should seek access to detailed 




to antiviral use across a large geographic cohort. Pneumococcal vaccine and seasonal 
influenza vaccine receipt could be comprehensively researched in the influenza positive 
population as factors that may influence the use of antibiotics and as additional study 
variables.  
Consistent with the literature in Chapter 2, Falsey et al. (2007) studied the impact 
of rapid diagnosis testing and the management of adults who were hospitalized with 
influenza; rapid influenza testing leads to reduced antibiotic use in hospitalized patients. 
Falsey et al. found positive influenza testing was associated with modest withholding or 
discontinuing antibiotics; however, a significant portion of the test positive patients at 
low risk for bacterial infection continued to receive antibiotics. Physicians were surveyed 
to assess the beliefs of being comfortable to discontinue antibiotics in patients with 
negative chest x-rays and negative bacterial cultures, and two thirds of the respondents 
believed they would be (Falsey et al., 2007). Medical record review, however, found that 
in practice these physicians did not discontinue antibiotic use (Falsey et al., 2007). 
Physicians are concerned about secondary bacterial infections with an influenza diagnosis 
and the ability to distinguish concomitant bacterial or viral infections during peak seasons 
for respiratory illness (Falsey et al., 2007). Even with sound medical evidence of no 
secondary or concomitant respiratory illness or disease, practitioners justified their choice 
to continue antibiotic use. 
Several studies have shown that diagnosis and treatment of influenza is not 
consistent among physicians. Linder et al. (2005) found that physicians prescribed 




medication to 19% of patients with an influenza diagnosis. Similar results from a study 
by Bonner et al. (2003) illustrated these same findings. As the literature suggests, there is 
clearly a need to further study the effects of antibiotic use during the influenza season 
among patient populations positive for influenza and the subsequent development of CDI 
outcome. 
Research could be expanded to include hospitals not using this proprietary 
surveillance and pharmacy module to identify a more representative population across the 
United States. A study that would include a larger sample size population has the 
potential to identify CDI among a cohort altering the distribution of the outcome and size 
of the effect, while increasing the power. Moreover, the effect of age as a variable could 
be further studied using categorization of age groups among the study population, such as 
distribution categories of ages from 18 to age 65 and older. 
The role of antibiotic induced Clostridium difficile diarrhea, infection, and colitis 
has been well documented ( Bartlett, 2011; Gaynes et al., 2004; Gerding, 2004; Nelson & 
Williams, 2007) while the discrete use of antivirals in the development of CDI has not 
(Colarian, 1988; Gellad et al., 2007; Gorschlüter et al., 2001; Pulvirenti et al., 2002;). 
Additional study of influenza positive populations using specific United States licensed 
prescription antiviral agents to treat influenza would add to the body of knowledge 
identified from this literature gap.  
Implications  
The results of this study offered an understanding of Clostridium difficile 




social change. Better understanding leads to new areas of inquiry and further study. The 
primary goal of antimicrobial stewardship is to improve clinical patient outcomes and 
minimize unintended adverse consequences due to inappropriate selection, dosing, and 
duration of these medication therapies. The incidence of CDAD before and after 
implementing antibiotic stewardship programs has been described across the United 
States with similar results (AHRQ, 2012). The removal or reducing the use of an 
offending antimicrobial agent can result in decreased CDAD (Garey, 2011; Nuila et al., 
2008). Although antimicrobial stewardship has become more common among hospitals, 
standardization of protocols and what stewardship details encompass are still being 
formulated. This has been fueled by recent governmental attention to improve antibiotic 
stewardship according to the metrics outlined within President Obama’s Executive Order-
Combating Antibiotic Resistant Bacteria (The White House, 2014). This research study 
revealed that there were inconsistencies in antiviral delivery and the need to further study 
the overall use of antibiotics in influenza positive populations, which can serve as a 
platform for implementing antimicrobial stewardship efforts. 
Knowledge from this epidemiologic study of seasonality of disease and antibiotics 
may have an influence at local and organizational levels. Healthcare providers may 
benefit from recognizing the effect that antibiotic delivery in hospitals has through more 
informed choices for use and pharmacologic recommendations. Increasing antibiotic 
stewardship may considerably reduce morbidity and mortality associated with CDI. 




for there to be implementation of comprehensive evidence-based Clostridium difficile 
measures.  
Antibiotic resistance and CDI are health care issues that affect the hospitalized 
patient and may have implications for affecting the general public once the patient is 
released from a healthcare setting, such as exposing the community population and 
environment to antibiotic resistance and CDI. Individuals need to increase their 
awareness of vaccine receipt to reduce the potential to contract influenza and spread to 
others. Additionally, individuals need to be an active participant in their own medical 
care and seek medical attention quickly to be diagnosed with influenza and receive the 
appropriate antivirals to lessen the severity and duration of illness. This action may 
reduce hospitalizations and risks for influenza complications. Individuals may also 
influence receipt of antibiotics by demanding them from medical care providers when 
they are not medically indicated, thereby ultimately affect CDI development. Families 
may be affected by the vaccine receipt in households as described in literature through 
herd immunity. Herd protection of a family or group may occur when a large proportion 
of individuals from that group are immune or immunized to influenza reducing exposure 
of those susceptible to the flu. The importance of vaccine receipt among family/groups 
and seeking diagnostic medical care and appropriate treatment for influenza has been 
recognized as an integral part of reducing household and group setting transmission. 
Although this study did not have access to data of vaccine receipt specifically, the study 




influenza. As a result, hospital medical staff, families, groups and individuals may benefit 
from the findings.  
Conclusion 
The purpose of this quantitative study was to examine the temporal progression of 
CDI incidence and possible influence of seasonal variation of influenza and antibiotic and 
antiviral use has on the incidence of CDI. The study aspired to enhance understanding 
about the relationship of CDI and seasonal influenza and the role/influence of 
antibimicrobial use and selection. Although the study findings did not prove to be 
significant for the three research questions with the premise that seasonal influenza leads 
to increased prescribing of antimicrobial agents which can lead to increased CDI; there 
was evidence to support recommended administration of antiviral medication was not 
consistent among influenza positive patients. Furthermore, the study indicated seasonal 
antimicrobial use that coincided with seasonal influenza did enable the identification of 
inappropriate prescribing patterns for antimicrobial agents. The future of antimicrobial 
stewardship is targeted Clostridium difficile reduction efforts as a complementary 
strategy to decrease CDI frequency by adressing inappropriate antibiotic use. 
Consequently, this study illustrated the need to highlight on the primary goals of 
antimicrobial stewardship: to focus on reducing inappropriate antimicrobial use and 
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